Clarivate Earnings Call: Margins Up, Growth Rebuilding

Clarivate Plc ((CLVT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Clarivate’s latest earnings call struck a cautiously upbeat tone as management balanced solid execution with lingering growth challenges. The company finally met its full-year guidance, highlighted improving recurring revenue metrics and strong cash generation, and set out ambitious margin and free cash flow targets for 2026. Yet leadership also acknowledged revenue headwinds from disposals, soft organic growth and the multi-year effort needed to fully turn around the IP business.

Delivered on Full-Year Guidance and Rebuilt Credibility

Clarivate reported that it hit its initial 2025 full-year guidance for the first time since 2019, a milestone management framed as evidence of improved discipline. Executives pointed to better sales execution, faster product innovation and tighter cost control as key drivers, arguing that these operational gains provide a stronger foundation heading into 2026.

ACV Momentum and Stronger Recurring Revenue Mix

Organic annual contract value grew nearly 2% in 2025, landing at the high end of the company’s range and improving by about 90 basis points year over year. Recurring revenue became more dominant, reaching 88% of total sales and a robust 93% within the Academia & Government segment, which should support more predictable cash flows despite softer transactional activity.

Robust Profitability and Cash Generation

Adjusted EBITDA surpassed $1.0 billion for the year, underscoring the underlying profitability of the portfolio despite flat revenue. Free cash flow reached $365 million, up about 2% versus 2024, and the company generated $160 million of operating cash and $89 million of free cash in the fourth quarter, giving management confidence in its ability to fund buybacks and debt reduction.

Revenue Performance and Earnings Trajectory

Fourth quarter revenue came in at $617 million, bringing full-year revenue to $2.455 billion, essentially flat versus the prior year once disposals are considered. Adjusted diluted EPS was $0.20 in Q4, up modestly sequentially, and management guided to around $0.75 in adjusted diluted EPS for 2026, implying roughly 9% growth even as reported revenue dips.

AI-Driven Product Innovation Gains Traction

Management highlighted 12 major product launches and AI-powered feature additions in 2025 as a core differentiator for future growth. The IP unit rolled out five generative AI tools, Academia & Government launched 10 AI assistants now used by more than 4,000 institutions, and Life Sciences saw some 11,000 active users on its AI-based assistants and workflow agents, while new integrations extend proprietary data into widely used AI platforms.

Early Recovery Signs in IP and Annuities

The Intellectual Property segment, which had previously been under pressure, showed initial improvement with annuities revenue up 270 basis points year over year. New IP offerings such as Derwent Patent search, Derwent Patent monitor and RiskMark are designed to modernize the toolkit and, over time, accelerate customer adoption in a market where the company acknowledges that a full turnaround will take several years.

Capital Allocation: Buybacks, Debt Retirement and Leverage

Clarivate continued to return capital to shareholders, using free cash flow to repurchase $225 million of stock and retire $56 million, or about 7%, of its outstanding shares. It also called $200 million of bonds, completing the final $100 million in early 2026, while keeping net leverage at about four times EBITDA and signaling that deleveraging will be the priority going forward, with buybacks remaining opportunistic.

Strategic Review and Potential LS&H Exit

In a major portfolio move, Clarivate launched a formal sale process for its Life Sciences & Health segment, aiming to sharpen its focus on Academia & Government and IP. Management emphasized that a potential transaction would be used to unlock value and bolster the balance sheet, positioning the remaining business for higher margin expansion and more targeted investment if the sale goes ahead.

Margin Expansion Despite Smaller Revenue Base

Even with a lower revenue outlook due to disposals, the company expects adjusted EBITDA margins to expand to nearly 43% in 2026 at the guidance midpoint, up about 200 basis points. Management reiterated that efficiency programs, mix shift toward higher-margin recurring revenue and reduced interest costs should allow modest EBITDA growth on a smaller top line.

Flat Organic Revenue and Transactional Drag

While ACV and subscriptions improved, total organic revenue was essentially flat for 2025 and slipped around 1% in the fourth quarter as transactional business continued to decline. Organic subscription revenue grew about 1%, but that progress was offset by weakening transactional demand, underscoring the need to further shift the model toward recurring products.

Disposals and Transactional Wind-Down Pressure Sales

Divestitures subtracted roughly $116 million from 2025 revenue and about $44 million from adjusted EBITDA versus the prior year. Looking ahead, management expects 2026 revenue to fall to around $2.36 billion at the midpoint, almost $100 million lower, as disposed businesses fully roll off and a transactional books line shuts down this summer, creating another step-down in reported sales.

Higher Operating Costs Pinch Q4 Profitability

Fourth quarter operating expenses rose as Clarivate continued to spend on innovation and paid higher incentive compensation tied to improved execution. These higher costs drove a $16 million year-over-year profit decline in the quarter, and full-year operating expenses also increased, reflecting management’s choice to prioritize long-term product and sales investments over near-term margin maximization.

Soft Net Income and Modest Underlying Growth

Net income for the fourth quarter was just $3 million, better than last year primarily because the prior period included a nonrecurring impairment charge. Recurring organic growth was only around 1% for the year, which management acknowledged as modest and reflective of the early stage of its turnaround, particularly in IP, where structural improvements have not yet fully translated into revenue acceleration.

Segment Turnaround Still a Multi-Year Journey

Executives were candid that parts of the IP portfolio remain in recovery mode after previous declines and that sustained organic growth will take time to materialize. The combination of new products, improved annuity trends and sales execution is expected to gradually rebuild momentum, but the company framed this as a multi-year transformation rather than a quick fix.

Seasonal and Timing Headwinds to Start 2026

Clarivate guided to a modest sequential pullback in the first quarter of 2026 due to renewal timing shifts and the reversal of prior-year patent renewal accelerations. Working capital is projected to be a roughly $20 million use of cash this year, largely tied to incentive payment timing, adding near-term pressure to free cash flow seasonality even as the full-year cash outlook improves.

Leverage Remains a Key Constraint

With net leverage still around four times EBITDA, the balance sheet remains a central factor in capital allocation decisions. Management reiterated that paying down debt will be the main use of incremental cash in 2026, even as it keeps some flexibility for share repurchases, reflecting the need to reduce financial risk while funding innovation.

Guidance Points to Cash-Led Growth in 2026

For 2026, Clarivate guided to 2–3% organic ACV growth and 1–2% recurring organic revenue growth, with total revenue around $2.36 billion as disposals and transactional exits weigh on the top line. The company expects recurring mix to rise to 88–90%, adjusted EBITDA margins to expand by about 200 basis points to nearly 43%, adjusted EPS to climb roughly 9% and free cash flow to grow to about $400 million, helped by lower interest, FX tailwinds and capex efficiencies despite working capital headwinds and a soft first quarter.

Clarivate’s earnings call painted the picture of a business leaning on cost discipline, product innovation and portfolio reshaping to drive value even as headline revenue dips. For investors, the story hinges on whether improving ACV trends, expanding margins and rising free cash flow can offset flat organic sales and execution risk in the IP turnaround, with the potential LS&H sale and deleveraging strategy as key catalysts to watch over the next year.